14-Nov-2024
Novel SOURCE study examining development of early COPD in ages 30 to 55
COPD FoundationPeer-Reviewed Publication
Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.
- Journal
- Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation
- Funder
- NIH/National Heart, Lung and Blood Institute, Amgen, AstraZeneca, MedImmune, Bayer, Bellerophon Therapeutics, Boehringer Ingelheim, Chiesi Farmaceutici, Forest Research Institute, Genentech, GlaxoSmithKline, Grifols, Ikaria, MGC Diagnostics, Novartis Pharma, Nycomed GmbH, ProterixBio, Regeneron Pharmaceuticals, Sanofi, Sunovion, Takeda Pharmaceutical Company, Theravance Biopharma US, Mylan, Viatris